Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules

Bioavailability of DHA-TG (Docosahexaenoic Triglyceride), DHA-PC (Docosahexaenoic Phosphatidylcholine) and AcedoPC (1-acetyl-2-docosahexaenoic-glycerophosphocholine) in Human

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02168738

Acronym

AceDoPC

Enrollment

Registered

2014-06-20

Start date

2014-03-31

Completion date

2015-04-30

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subject

Keywords

nutrition

Brief summary

The purpose of this study is to compare three lipidic forms of DHA in their metabolic pathway in human by using 13C labeled molecules. The circulating form of DHA plays a major role in his cerebral incorporation. The aim of this research is to confirm that some lipidic forms are best carriers for the cerebral incorporation in studying 13C-DHA distribution in plasma lipids and blood cells.

Interventions

DRUG13-C labeled AceDoPC-DHA

Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C. The dose contains 50 mg 13C-DHA. The wash-out period is four months

DRUG13-C labeled TG-DHA

DRUG13-C labeled PC-DHA

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

60 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male * Aged of 60 to 70 years * Body Mass Index of 20 to 30 kg/m2 * Glycaemic and lipid parameters normal

Exclusion criteria

* Smokers more than ten cigarettes/day * Medical history of personal or family dyslipidemia * Medication that could interfere with lipid metabolism

Design outcomes

Primary

Measure	Time frame	Description
Concentration of 13C-DHA in red blood cells	At Day 1	6 hours after product ingestion

Secondary

Measure	Time frame	Description
Concentration of 13C-DHA in plasma lipids	At Day 1	6 hours after product ingestion
Concentration of 13C-DHA in platelets	At Day 1	6 hours after product ingestion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026